These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
674 related articles for article (PubMed ID: 17440112)
21. Frequent p16-independent inactivation of p14ARF in human melanoma. Freedberg DE; Rigas SH; Russak J; Gai W; Kaplow M; Osman I; Turner F; Randerson-Moor JA; Houghton A; Busam K; Timothy Bishop D; Bastian BC; Newton-Bishop JA; Polsky D J Natl Cancer Inst; 2008 Jun; 100(11):784-95. PubMed ID: 18505964 [TBL] [Abstract][Full Text] [Related]
22. Alterations of p14 López F; Sampedro T; Llorente JL; Hermsen M; Álvarez-Marcos C Pathol Oncol Res; 2017 Jan; 23(1):63-71. PubMed ID: 27377733 [TBL] [Abstract][Full Text] [Related]
23. Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. Aveyard JS; Knowles MA J Mol Diagn; 2004 Nov; 6(4):356-65. PubMed ID: 15507675 [TBL] [Abstract][Full Text] [Related]
24. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113 [TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Edmunds SC; Kelsell DP; Hungerford JL; Cree IA Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501 [TBL] [Abstract][Full Text] [Related]
26. Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma. Kanellou P; Zaravinos A; Zioga M; Spandidos DA Br J Dermatol; 2009 Jun; 160(6):1215-21. PubMed ID: 19298278 [TBL] [Abstract][Full Text] [Related]
27. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049 [TBL] [Abstract][Full Text] [Related]
28. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164 [TBL] [Abstract][Full Text] [Related]
29. Alterations in RD(INK4/ARF) -mediated en bloc regulation of the INK4-ARF locus in human squamous cell carcinoma of the head and neck. Poi MJ; Knobloch TJ; Sears MT; Warner BM; Uhrig LK; Weghorst CM; Li J Mol Carcinog; 2015 Jul; 54(7):532-42. PubMed ID: 24302590 [TBL] [Abstract][Full Text] [Related]
30. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc. Haviernik P; Schmidt M; Hu X; Wolff L Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863 [TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Kotake Y; Nakagawa T; Kitagawa K; Suzuki S; Liu N; Kitagawa M; Xiong Y Oncogene; 2011 Apr; 30(16):1956-62. PubMed ID: 21151178 [TBL] [Abstract][Full Text] [Related]
32. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621 [TBL] [Abstract][Full Text] [Related]
33. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. Genescà E; Lazarenkov A; Morgades M; Berbis G; Ruíz-Xivillé N; Gómez-Marzo P; Ribera J; Juncà J; González-Pérez A; Mercadal S; Guardia R; Artola MT; Moreno MJ; Martínez-López J; Zamora L; Barba P; Gil C; Tormo M; Cladera A; Novo A; Pratcorona M; Nomdedeu J; González-Campos J; Almeida M; Cervera J; Montesinos P; Batlle M; Vives S; Esteve J; Feliu E; Solé F; Orfao A; Ribera JM J Hematol Oncol; 2018 Jul; 11(1):96. PubMed ID: 30041662 [TBL] [Abstract][Full Text] [Related]
34. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909 [TBL] [Abstract][Full Text] [Related]
35. Germline mutation of ARF in a melanoma kindred. Hewitt C; Lee Wu C; Evans G; Howell A; Elles RG; Jordan R; Sloan P; Read AP; Thakker N Hum Mol Genet; 2002 May; 11(11):1273-9. PubMed ID: 12019208 [TBL] [Abstract][Full Text] [Related]
36. Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis. Tang S; Luo H; Yu J; Yang D; Shu J Chin Med J (Engl); 2003 Jul; 116(7):1083-7. PubMed ID: 12890389 [TBL] [Abstract][Full Text] [Related]
37. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981 [TBL] [Abstract][Full Text] [Related]
38. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value. Meseure D; Vacher S; Alsibai KD; Nicolas A; Chemlali W; Caly M; Lidereau R; Pasmant E; Callens C; Bieche I Mol Cancer Res; 2016 Jul; 14(7):623-33. PubMed ID: 27102007 [TBL] [Abstract][Full Text] [Related]
39. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression. Ming Z; Lim SY; Rizos H Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392 [TBL] [Abstract][Full Text] [Related]
40. Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. Poi MJ; Drosdeck J; Frankel WL; Muscarella P; Li J Pancreas; 2014 Oct; 43(7):1009-13. PubMed ID: 25003221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]